-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, BeiGene submitted a new indication of belintoomab for injection marketing application on the grounds of "new varieties, dosage forms and specifications of children’s drugs that meet the physiological characteristics of children, and drugs that meet conditional approval".
Belintoomab is a bispecific antibody targeting CD3-CD19 developed based on Amgen's most advanced bispecific T cell adapter system (BiTE®).
Belinto Oumab was approved by the NMPA on December 4 last year through the priority review method for the treatment of adult relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).
Belintoux received accelerated FDA approval for marketing as early as December 2014.